150 related articles for article (PubMed ID: 17470513)
1. Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome.
Cleary S; Phillips JK; Huynh TT; Pacak K; Elkahloun AG; Barb J; Worrell RA; Goldstein DS; Eisenhofer G
J Endocrinol; 2007 May; 193(2):225-33. PubMed ID: 17470513
[TBL] [Abstract][Full Text] [Related]
2. Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
Huynh TT; Pacak K; Brouwers FM; Abu-Asab MS; Worrell RA; Walther MM; Elkahloun AG; Goldstein DS; Cleary S; Eisenhofer G
Eur J Endocrinol; 2005 Oct; 153(4):551-63. PubMed ID: 16189177
[TBL] [Abstract][Full Text] [Related]
3. Chromogranin a expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
Cleary S; Phillips JK; Huynh TT; Pacak K; Fliedner S; Elkahloun AG; Munson P; Worrell RA; Eisenhofer G
Horm Metab Res; 2007 Dec; 39(12):876-83. PubMed ID: 18046660
[TBL] [Abstract][Full Text] [Related]
4. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes.
Eisenhofer G; Walther MM; Huynh TT; Li ST; Bornstein SR; Vortmeyer A; Mannelli M; Goldstein DS; Linehan WM; Lenders JW; Pacak K
J Clin Endocrinol Metab; 2001 May; 86(5):1999-2008. PubMed ID: 11344198
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of erythropoietin and its receptor in von hippel-lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas.
Vogel TW; Brouwers FM; Lubensky IA; Vortmeyer AO; Weil RJ; Walther MM; Oldfield EH; Linehan WM; Pacak K; Zhuang Z
J Clin Endocrinol Metab; 2005 Jun; 90(6):3747-51. PubMed ID: 15769989
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
Huynh TT; Pacak K; Wong DL; Linehan WM; Goldstein DS; Elkahloun AG; Munson PJ; Eisenhofer G
Ann N Y Acad Sci; 2006 Aug; 1073():241-52. PubMed ID: 17102092
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre.
Patócs A; Karádi E; Tóth M; Varga I; Szücs N; Balogh K; Majnik J; Gláz E; Rácz K
Eur J Cancer Prev; 2004 Oct; 13(5):403-9. PubMed ID: 15452453
[TBL] [Abstract][Full Text] [Related]
8. Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1.
Butz JJ; Yan Q; McKenzie TJ; Weingarten TN; Cavalcante AN; Bancos I; Young WF; Schroeder DR; Martin DP; Sprung J
Surgery; 2017 Dec; 162(6):1259-1269. PubMed ID: 28919049
[TBL] [Abstract][Full Text] [Related]
9. Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2.
Koch CA; Mauro D; Walther MM; Linehan WM; Vortmeyer AO; Jaffe R; Pacak K; Chrousos GP; Zhuang Z; Lubensky IA
Endocr Pathol; 2002; 13(1):17-27. PubMed ID: 12114747
[TBL] [Abstract][Full Text] [Related]
10. Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B.
Brouwers FM; Gläsker S; Nave AF; Vortmeyer AO; Lubensky I; Huang S; Abu-Asab MS; Eisenhofer G; Weil RJ; Park DM; Linehan WM; Pacak K; Zhuang Z
Endocr Relat Cancer; 2007 Jun; 14(2):463-71. PubMed ID: 17639059
[TBL] [Abstract][Full Text] [Related]
11. Bilateral phaeochromocytomas in von Hippel-Lindau disease: diagnosis by adrenal vein sampling and catecholamine assay.
Chew SL; Dacie JE; Reznek RH; Newbould EC; Sheaves R; Trainer PJ; Lowe DG; Shand WS; Hungerford J; Besser GM
Q J Med; 1994 Jan; 87(1):49-54. PubMed ID: 8140217
[TBL] [Abstract][Full Text] [Related]
12. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma.
Eisenhofer G; Pacak K; Huynh TT; Qin N; Bratslavsky G; Linehan WM; Mannelli M; Friberg P; Grebe SK; Timmers HJ; Bornstein SR; Lenders JW
Endocr Relat Cancer; 2011 Feb; 18(1):97-111. PubMed ID: 21051559
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.
Eng C; Crossey PA; Mulligan LM; Healey CS; Houghton C; Prowse A; Chew SL; Dahia PL; O'Riordan JL; Toledo SP
J Med Genet; 1995 Dec; 32(12):934-7. PubMed ID: 8825918
[TBL] [Abstract][Full Text] [Related]
14. [Genetic tests in oncology practice with emphasis on the RET oncogene and VHL tumor suppressor gene].
Nesković G; Stanojević B; Palmar I; Dimitrijević B
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():52-7. PubMed ID: 12584999
[TBL] [Abstract][Full Text] [Related]
15. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL.
Woodward ER; Eng C; McMahon R; Voutilainen R; Affara NA; Ponder BA; Maher ER
Hum Mol Genet; 1997 Jul; 6(7):1051-6. PubMed ID: 9215674
[TBL] [Abstract][Full Text] [Related]
16. Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours.
Srirangalingam U; Khoo B; Walker L; MacDonald F; Skelly RH; George E; Spooner D; Johnston LB; Monson JP; Grossman AB; Drake WM; Akker SA; Pollard PJ; Plowman N; Avril N; Berney DM; Burrin JM; Reznek RH; Kumar VK; Maher ER; Chew SL
Endocr Relat Cancer; 2009 Jun; 16(2):515-25. PubMed ID: 19208735
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas.
Margetts CD; Astuti D; Gentle DC; Cooper WN; Cascon A; Catchpoole D; Robledo M; Neumann HP; Latif F; Maher ER
Endocr Relat Cancer; 2005 Mar; 12(1):161-72. PubMed ID: 15788647
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide Y in multiple endocrine neoplasia: release during surgery for phaeochromocytoma.
Connell JM; Corder R; Asbury J; Macpherson S; Inglis GC; Lowry P; Burt AD; Semple PF
Clin Endocrinol (Oxf); 1987 Jan; 26(1):75-84. PubMed ID: 2879655
[TBL] [Abstract][Full Text] [Related]
19. Von Hippel-Lindau disease and endocrine tumour susceptibility.
Woodward ER; Maher ER
Endocr Relat Cancer; 2006 Jun; 13(2):415-25. PubMed ID: 16728571
[TBL] [Abstract][Full Text] [Related]
20. High levels of expression of neuropeptide Y mRNA in human phaeochromocytomas.
Higuchi H; Iwasa A; Yokokawa K
Clin Exp Pharmacol Physiol; 1994 May; 21(5):359-65. PubMed ID: 7955545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
